WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009129544) MICROSPHERE-BASED COMPOSITION FOR PREVENTING AND/OR REVERSING NEW-ONSET AUTOIMMUNE DIABETES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/129544    International Application No.:    PCT/US2009/041167
Publication Date: 22.10.2009 International Filing Date: 20.04.2009
IPC:
C12N 15/11 (2006.01)
Applicants: BAXTER INTERNATIONAL INC. [US/US]; One Baxter Parkway Deerfield, IL 60015 (US) (For All Designated States Except US).
BAXTER HEALTHCARE S.A. [CH/CH]; Hertistrasse 2 CH-8304 Wallisellen (CH) (For All Designated States Except US).
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION [US/US]; 200 Gardner Steel Conference Center Thackeray & O'Hara Streets Pittsburgh, PA 15260 (US) (For All Designated States Except US).
BROWN, Larry, R. [US/US]; (US) (For US Only).
GIANNOUKAKIS, Nick [US/US]; (US) (For US Only).
TRUCCO, Massimo [US/US]; (US) (For US Only)
Inventors: BROWN, Larry, R.; (US).
GIANNOUKAKIS, Nick; (US).
TRUCCO, Massimo; (US)
Agent: ALLIKIAN, Michael, J.; (US)
Priority Data:
61/048,246 28.04.2008 US
61/046,034 18.04.2008 US
Title (EN) MICROSPHERE-BASED COMPOSITION FOR PREVENTING AND/OR REVERSING NEW-ONSET AUTOIMMUNE DIABETES
(FR) COMPOSITION À BASE DE MICROSPHÈRES POUR PRÉVENIR ET/OU INVERSER UNE NOUVELLE APPARITION DE DIABÈTE AUTO-IMMUN
Abstract: front page image
(EN)A method is provided that includes using an antisense approach to reverse and/or delay an autoimmune diabetes condition in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.
(FR)L’invention concerne un procédé comprenant l’utilisation d’une approche antisens pour inverser et/ou retarder une condition de diabète auto-immun in vivo. Les oligonucléotides sont ciblés pour se lier à des produits de transcription primaires CD40, CD80, CD86 et leurs combinaisons.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)